Literature DB >> 11472746

The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations.

D J Gaughan1, L A Kluijtmans, S Barbaux, D McMaster, I S Young, J W Yarnell, A Evans, A S Whitehead.   

Abstract

Epidemiological evidence has revealed that an elevated plasma homocysteine level (hyperhomocysteinemia) confers an increased risk of cardiovascular disease and neural tube defects. Hyperhomocysteinemia is caused by both nutritional (e.g. folate, vitamins B(6) and B(12)) and genetic factors, including functional polymorphisms of key enzymes involved in homocysteine metabolism. One such enzyme, methionine synthase reductase (MTRR), maintains adequate levels of methylcob(III)alamin, the activated cofactor for methionine synthase, which catalyzes the remethylation of homocysteine to methionine. A common MTRR polymorphism, i.e. a 66 A-->G substitution specifying an isoleucine to methionine substitution (I22M), was recently identified. To assess the influence of this polymorphism on total plasma homocysteine (tHcy), we undertook a genotype/phenotype analysis in a study population of 601 Northern-Irish men, aged 30--49, for which biochemical and genetic data relevant to folate/homocysteine metabolism had already been acquired. The 66AA genotype has a frequency of 29% in this population. We established that there was a significant influence of MTRR genotype on tHcy ranking (P=0.004) and that the 66AA genotype contributes to a moderate increase in tHcy levels across the distribution [OR 1.59 (95% CI: 1.10--2.25) for the 66AA genotype to be in the upper half of the tHcy distribution, P=0.03]. The homocysteine-elevating effect of the 66AA genotype is independent of serum folate, vitamin B(12) and vitamin B(6) levels. Based on published estimates of the enhanced cardiovascular disease risk conferred by defined increments of plasma tHcy, we estimate that 66AA homozygotes have, on average, an approximately 4% increase in cardiovascular disease risk compared to 66GG homozygotes. This study provides the first evidence that the MTRR A66G polymorphism significantly influences the circulating tHcy concentration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472746     DOI: 10.1016/s0021-9150(00)00739-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  68 in total

1.  Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population.

Authors:  C L Relton; C S Wilding; M S Pearce; A J Laffling; P A Jonas; S A Lynch; E J Tawn; J Burn
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

2.  Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes.

Authors:  Sara R Zwart; Jesse F Gregory; Steven H Zeisel; Charles R Gibson; Thomas H Mader; Jason M Kinchen; Per M Ueland; Robert Ploutz-Snyder; Martina A Heer; Scott M Smith
Journal:  FASEB J       Date:  2015-08-27       Impact factor: 5.191

3.  Olecular mechanism underlying the myeloperoxidase induced apoptosis of HUVEC-12 cells.

Authors:  Mao Ouyang; Hengdao Liu; Kan Yang; Weihong Jiang; Qi Ding; Xunzhang Yu; Wu Chen
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  Association of folate metabolism gene polymorphisms and haplotype combination with pulmonary embolism risk in Chinese Han population.

Authors:  Xin Li; Ling Weng; Baihe Han; Yingnan Dai; Li Cha; Shujun Yan; Enze Jin
Journal:  Mamm Genome       Date:  2017-05-12       Impact factor: 2.957

5.  Surrogate genetics and metabolic profiling for characterization of human disease alleles.

Authors:  Jacob A Mayfield; Meara W Davies; Dago Dimster-Denk; Nick Pleskac; Sean McCarthy; Elizabeth A Boydston; Logan Fink; Xin Xin Lin; Ankur S Narain; Michael Meighan; Jasper Rine
Journal:  Genetics       Date:  2012-01-20       Impact factor: 4.562

6.  Association of polymorphisms in DNMT1, DNMT3A, DNMT3B, MTHFR and MTRR genes with global DNA methylation levels and prognosis of autoimmune thyroid disease.

Authors:  Y Arakawa; M Watanabe; N Inoue; M Sarumaru; Y Hidaka; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk.

Authors:  Susan E Steck; Temitope Keku; Lesley M Butler; Joseph Galanko; Beri Massa; Robert C Millikan; Robert S Sandler
Journal:  J Nutrigenet Nutrigenomics       Date:  2008-06-02

8.  Gene-gene interactions in the folate metabolic pathway and the risk of conotruncal heart defects.

Authors:  Philip J Lupo; Elizabeth Goldmuntz; Laura E Mitchell
Journal:  J Biomed Biotechnol       Date:  2010-01-12

9.  Functional polymorphisms of folate-metabolizing enzymes in relation to homocysteine concentrations in systemic lupus erythematosus.

Authors:  Carolyn M Summers; Andrew J Cucchiara; Eleni Nackos; Andrea L Hammons; Elisabeth Mohr; Alexander S Whitehead; Joan M Von Feldt
Journal:  J Rheumatol       Date:  2008-09-01       Impact factor: 4.666

10.  Lack of association between genetic polymorphisms in enzymes associated with folate metabolism and unexplained reduced sperm counts.

Authors:  Celia Ravel; Sandra Chantot-Bastaraud; Clementine Chalmey; Luis Barreiro; Isabelle Aknin-Seifer; Jerome Pfeffer; Isabelle Berthaut; E Emmanuelle Mathieu; Jacqueline Mandelbaum; Jean-Pierre Siffroi; Ken McElreavey; Anu Bashamboo
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.